You are here

  • Home
  • Archive
  • Volume 7, Issue 3
  • Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials

Article metrics

Article menu

Download PDFPDF

XML
Oncology
Research
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials

 

Online download statistics by month:

Online download statistics by month: January 2018 to April 2024

AbstractFullPdf
Jan 201810710742
Feb 2018908627
Mar 201811311354
Apr 201810810831
May 201812111929
Jun 2018787928
Jul 2018808014
Aug 2018908822
Sep 2018858518
Oct 201810910931
Nov 201816416450
Dec 2018959531
Jan 201913613645
Feb 201926225543
Mar 201919519148
Apr 2019878747
May 201913712241
Jun 2019888826
Jul 201910810530
Aug 2019827943
Oct 201910410335
Nov 20191019831
Dec 20191029922
Jan 202011311240
Feb 20201602159981
Mar 20201384137763
May 202014413924
Jun 2020848485
Jul 202015215063
Aug 2020827836
Sep 202019718346
Oct 20201474147067
Nov 2020877640
Dec 202012111835
Jan 2021929036
Feb 202111710636
Mar 202115214259
Apr 2021837844
May 2021625929
Jun 2021514824
Jul 20211009926
Aug 2021504738
Sep 2021727045
Oct 2021615944
Nov 2021807957
Dec 2021868528
Jan 2022757723
Feb 2022685125
Mar 2022514729
Apr 202210310830
May 202215615251
Jun 2022747450
Jul 2022484613
Aug 2022444221
Sep 2022949434
Oct 2022575131
Nov 202210210133
Dec 2022635819
Jan 2023615226
Feb 2023393219
Mar 2023605226
Apr 2023433820
May 2023443627
Jun 202321177
Jul 2023433921
Aug 2023242312
Sep 2023322814
Oct 2023493314
Nov 2023615325
Dec 2023636219
Jan 2024353516
Feb 2024323228
Mar 2024645296
Apr 2024583842
Total10752104672605